Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates.
Emerg Microbes Infect
; 10(1): 629-637, 2021 Dec.
Article
in English
| MEDLINE | ID: covidwho-1124369
ABSTRACT
COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different combinations of the four types of leading COVID-19 vaccine candidates that are undergoing clinical trials in China were tested in a mouse model. Our results showed that sequential immunization with adenovirus vectored vaccine followed by inactivated/recombinant subunit/mRNA vaccine administration specifically increased levels of neutralizing antibodies and promoted the modulation of antibody responses to predominantly neutralizing antibodies. Moreover, a heterologous prime-boost regimen with an adenovirus vector vaccine also improved Th1-biased T cell responses. Our results provide new ideas for the development and application of COVID-19 vaccines to control the SARS-CoV-2 pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Vaccines, Synthetic
/
Immunization, Secondary
/
Vaccines, Subunit
/
Adenovirus Vaccines
/
COVID-19 Vaccines
/
Antibodies, Viral
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Animals
Language:
English
Journal:
Emerg Microbes Infect
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS